At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 173 enrolled
Drug / intervention
Lenvatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
In Brief
A Phase 2 clinical trial evaluating Lenvatinib and Everolimus for Metastatic Renal Cell Carcinoma. Completed, enrolled 173 participants across 37 sites in 5 countries.
Detailed Summary
This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesCzechia, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartAug 2010
Primary CompletionJun 2014
Study CompletionFeb 2018
TodayJul 2026
First PostedJun 3, 2010
Enrollment StartAug 5, 2010
Primary CompletionJun 13, 2014
Study CompletionFeb 8, 2018
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.1 years ago
Interventions
Lenvatinibdrug
taken orally, once a day
Everolimusdrug
taken orally, once a day